Clinical activity of vofatamab, an FGFR3 selective antibody in combination with pembrolizumab in metastatic urothelial carcinoma (mUC), updated follow up results from the interim analysis of FIERCE-22
Publication/Presentation Date
10-2019
Volume
18
Issue
8
First Page
3046
Last Page
3046
Published In/Presented At
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
Department(s)
Administration and Leadership
Document Type
Article
COinS